SLDB Price / Book | Solid Biosciences Inc.

Solid Biosciences Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Solid Biosciences Inc. price/book ratio for the quarter ending 2026-06-30 was 2.81, a 91.58% increase year-over-year.
Solid Biosciences Inc. price/book ratio for the quarter ending 2026-03-31 was 1.89, a 94.47% increase year-over-year.
Solid Biosciences Inc. price/book ratio for the quarter ending 2025-12-31 was 2.48, a 110.52% increase year-over-year.
Solid Biosciences Inc. price/book ratio for the quarter ending 2025-09-30 was 2.21, a 36.15% increase year-over-year.
Solid Biosciences Inc. price/book ratio for fiscal 2026 was 2.81.
Solid Biosciences Inc. price/book ratio for fiscal 2025 was 2.48, a 110.52% increase from fiscal 2024.
Solid Biosciences Inc. price/book ratio for fiscal 2024 was 1.18, a 19.18% increase from fiscal 2023.
Solid Biosciences Inc. price/book ratio for fiscal 2023 was 0.99, a 99.10% increase from fiscal 2022.

Available history: 2018-03-31 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	2.81	$1.05B	$374.08M
2026-03-31	1.89	$708.44M	$374.13M
2025-12-31	2.48	$446.96M	$180.01M
2025-09-30	2.21	$482.09M	$217.95M
2025-06-30	1.47	$378.7M	$258.29M
2025-03-31	0.97	$286.72M	$294.46M
2024-12-31	1.18	$161.87M	$137.25M
2024-09-30	1.62	$271.34M	$167.02M
2024-06-30	1.13	$218.58M	$193.25M
2024-03-31	2.39	$503.94M	$210.72M
2023-12-31	0.99	$125.17M	$126.48M
2023-09-30	0.35	$50.56M	$144.36M
2023-06-30	0.64	$105.03M	$163.73M
2023-03-31	0.5	$92.78M	$183.79M
2022-12-31	0.5	$105.22M	$211.67M
2022-09-30	0.37	$52.77M	$143.28M
2022-06-30	6.43	$1.04B	$162.24M
2022-03-31	10.94	$2.03B	$185.51M
2021-12-31	0.93	$193.1M	$208.21M
2021-09-30	17.7	$3.95B	$223.36M
2021-06-30	25.45	$6.06B	$237.94M
2021-03-31	36.16	$9.15B	$253M
2020-12-31	73.08	$9.65B	$132.09M
2020-09-30	63.25	$1.41B	$22.23M
2020-06-30	49.64	$2.02B	$40.71M
2020-03-31	29.26	$1.65B	$56.46M
2019-12-31	38.35	$3.07B	$80.05M
2019-09-30	65.74	$7.13B	$108.53M
2019-06-30	39.91	$3.05B	$76.5M
2019-03-31	49.31	$4.89B	$99.11M
2018-12-31	113.78	$14.24B	$125.18M
2018-09-30	172.85	$25.08B	$145.07M
2018-06-30	116.72	$18.94B	$162.29M
2018-03-31	22.3	$3.99B	$178.95M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	2.81	$1.05B	$374.08M
2025-12-31	2.48	$446.96M	$180.01M
2024-12-31	1.18	$161.87M	$137.25M
2023-12-31	0.99	$125.17M	$126.48M
2022-12-31	0.5	$105.22M	$211.67M
2021-12-31	0.93	$193.1M	$208.21M
2020-12-31	73.08	$9.65B	$132.09M
2019-12-31	38.35	$3.07B	$80.05M
2018-12-31	113.78	$14.24B	$125.18M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Attovia Therapeutics, Inc. (ATTO)	United States	$0.828B
4D Molecular Therapeutics, Inc. (FDMT)	United States	$0.733B	-4.10
Candel Therapeutics, Inc. (CADL)	United States	$0.885B	-8.86
Sana Biotechnology, Inc. (SANA)	United States	$0.886B	-4.92
Odyssey Therapeutics, Inc. (ODTX)	United States	$0.960B
Aura Biosciences, Inc. (AURA)	United States	$0.639B	-5.61
Cullinan Therapeutics, Inc. (CGEM)	United States	$0.993B	-5.72
Monte Rosa Therapeutics, Inc. (GLUE)	United States	$1.002B	-12.81
Allogene Therapeutics, Inc. (ALLO)	United States	$0.574B	-4.33
Prime Medicine, Inc. (PRME)	United States	$0.557B	-3.54